Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Benitec Biopharma Inc.NASDAQ: BNTC
Net Debt · Q3 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q3 FY2026 net debt was -$183.89M, compared with -$102.62M a year earlier.
Context
- Net debt amounted to 98.3% of total assets at the end of Q3 FY2026, up 0.8 pp from a year earlier.
- Net debt grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -79.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (96.9M) USD
- Year-over-year change
- -91.6%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | (96.9M) | -91.6% |
| FY2024 | 2024-06-30 | (50.58M) | -2537.2% |
| FY2023 | 2023-06-30 | (1.92M) | +41.0% |
| FY2022 | 2022-06-30 | (3.25M) | +83.4% |
| FY2021 | 2021-06-30 | (19.56M) | — |
Net Debt vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 net debt of -$183.89M is the 8th highest of the 10 companies compared; the peer median is -$33.55M.
- Its year-over-year change of -79.2% is the 8th highest of 10, against a peer median of +9.3%.
- Net debt amounts to 98.3% of total assets for BNTC, versus a peer median of 30.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $121.61M | +20.9% | +76.0% | 771.7% | |
| Mar 2026 | $30.27M | +25.1% | — | 11.1% | |
| Mar 2026 | $1.44M | +124.1% | — | 2.5% | |
| Mar 2026 | -$32.49M | -28.7% | — | 15.2% | |
| Mar 2026 | -$33.55M | +26.5% | — | 30.6% | |
| Mar 2026 | -$50.97M | -123.7% | — | 9.7% | |
| Mar 2026 | -$115.03M | -101.0% | — | 43.7% | |
| Mar 2026 | -$183.89M | -79.2% | — | 98.3% | |
| Dec 2025 | -$234.31M | +9.3% | — | 43.8% | |
| Mar 2026 | -$277.07M | -48.2% | — | 65.5% | |
| Peer median (excluding BNTC) | -$33.55M | +9.3% | +76.0% | 30.6% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.